132 related articles for article (PubMed ID: 10096246)
1. Comparative immunocytochemical assessment of isolated carcinoma cells in lymph nodes and bone marrow of patients with clinically localized prostate cancer.
Köllermann J; Heseding B; Helpap B; Köllermann MW; Pantel K
Int J Cancer; 1999 Apr; 84(2):145-9. PubMed ID: 10096246
[TBL] [Abstract][Full Text] [Related]
2. Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy.
Potter SR; Mangold LA; Shue MJ; Taylor DC; Lecksell KL; Epstein JI; Walsh PC; Partin AW
Cancer; 2000 Dec; 89(12):2577-86. PubMed ID: 11135219
[TBL] [Abstract][Full Text] [Related]
3. Methylation-specific PCR for DNA-based detection of occult tumor cells in lymph nodes of prostate cancer patients.
Köllermann J; Müller M; Goessl C; Krause H; Helpap B; Pantel K; Miller K
Eur Urol; 2003 Nov; 44(5):533-8. PubMed ID: 14572750
[TBL] [Abstract][Full Text] [Related]
4. Comparison between Use of PSA Kinetics and Bone Marrow Micrometastasis to Define Local or Systemic Relapse in Men with Biochemical Failure after Radical Prostatectomy for Prostate Cancer.
Murray NP; Reyes E; Fuentealba C; Orellana N; Jacob O
Asian Pac J Cancer Prev; 2015; 16(18):8387-90. PubMed ID: 26745090
[TBL] [Abstract][Full Text] [Related]
5. Limitations of detection of bone-marrow micrometastasis in prostate carcinoma patients by CK18/PSA immunocytochemistry and PSA RT-PCR.
Albers P; Ko Y; Wardelmann E; Schmidt D; Adam M; Vetter H; Müller SC
Anticancer Res; 2000; 20(3B):2107-11. PubMed ID: 10928161
[TBL] [Abstract][Full Text] [Related]
6. Does the immunocytochemical detection of epithelial cells in bone marrow (micrometastasis) influence the time to biochemical relapse after radical prostatectomy?
Weckermann D; Wawroschek F; Krawczak G; Haude KH; Harzmann R
Urol Res; 1999 Aug; 27(4):285-90. PubMed ID: 10460901
[TBL] [Abstract][Full Text] [Related]
7. Immunocytochemical monitoring of micrometastatic disease: reduction of prostate cancer cells in bone marrow by androgen deprivation.
Pantel K; Enzmann T; Köllermann J; Caprano J; Riethmüller G; Köllermann MW
Int J Cancer; 1997 May; 71(4):521-5. PubMed ID: 9178803
[TBL] [Abstract][Full Text] [Related]
8. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes.
Shariat SF; Roudier MP; Wilcox GE; Kattan MW; Scardino PT; Vessella RL; Erdamar S; Nguyen C; Wheeler TM; Slawin KM
Cancer Res; 2003 Aug; 63(15):4662-70. PubMed ID: 12907647
[TBL] [Abstract][Full Text] [Related]
9. Topography of lymph node metastases in prostate cancer patients undergoing radical prostatectomy and extended lymphadenectomy: results of a combined molecular and histopathologic mapping study.
Heck MM; Retz M; Bandur M; Souchay M; Vitzthum E; Weirich G; Mollenhauer M; Schuster T; Autenrieth M; Kübler H; Maurer T; Thalgott M; Herkommer K; Gschwend JE; Nawroth R
Eur Urol; 2014 Aug; 66(2):222-9. PubMed ID: 23465520
[TBL] [Abstract][Full Text] [Related]
10. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
11. Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value.
Weckermann D; Müller P; Wawroschek F; Harzmann R; Riethmüller G; Schlimok G
J Urol; 2001 Aug; 166(2):699-703. PubMed ID: 11458120
[TBL] [Abstract][Full Text] [Related]
12. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
Raj GV; Partin AW; Polascik TJ
Cancer; 2002 Feb; 94(4):987-96. PubMed ID: 11920467
[TBL] [Abstract][Full Text] [Related]
14. Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era.
Dorin RP; Lieskovsky G; Fairey AS; Cai J; Daneshmand S
Urol Oncol; 2013 Nov; 31(8):1441-7. PubMed ID: 22516714
[TBL] [Abstract][Full Text] [Related]
15. Immunocytochemical detection of isolated tumour cells in bone marrow of patients with untreated stage C prostatic cancer.
Pantel K; Aignherr C; Köllermann J; Caprano J; Riethmüller G; Köllermann MW
Eur J Cancer; 1995 Sep; 31A(10):1627-32. PubMed ID: 7488413
[TBL] [Abstract][Full Text] [Related]
16. Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction.
Gao CL; Dean RC; Pinto A; Mooneyhan R; Connelly RR; McLeod DG; Srivastava S; Moul JW
J Urol; 1999 Apr; 161(4):1070-6. PubMed ID: 10081840
[TBL] [Abstract][Full Text] [Related]
17. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer.
Weckermann D; Polzer B; Ragg T; Blana A; Schlimok G; Arnholdt H; Bertz S; Harzmann R; Klein CA
J Clin Oncol; 2009 Apr; 27(10):1549-56. PubMed ID: 19237635
[TBL] [Abstract][Full Text] [Related]
18. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.
Miyake H; Kurahashi T; Hara I; Takenaka A; Fujisawa M
BJU Int; 2007 Feb; 99(2):315-20. PubMed ID: 17155986
[TBL] [Abstract][Full Text] [Related]
19. The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer.
Schiavina R; Manferrari F; Garofalo M; Bertaccini A; Vagnoni V; Guidi M; Borghesi M; Baccos A; Morselli-Labate AM; Concetti S; Martorana G
BJU Int; 2011 Oct; 108(8):1262-8. PubMed ID: 21446934
[TBL] [Abstract][Full Text] [Related]
20. Screening for occult nodal metastasis in localized carcinoma of the prostate.
Gomella LG; White JL; McCue PA; Byrne DS; Mulholland SG
J Urol; 1993 Apr; 149(4):776-8. PubMed ID: 7681116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
